ULTRAGENYX PHARMACEUTICAL

• ULTRAGENYX PHARMACEUTICAL INC. $1,850,000 In-house, the client's own filings · 7 filings
• MEHLMAN CONSULTING, INC. $420,000 Outside firm · 7 filings
• MILLER STRATEGIES, LLC $230,000 Outside firm · 4 filings
• ALPINE GROUP PARTNERS, LLC. $160,000 Outside firm · 4 filings
• AVIVA STRATEGIES (FKA MGB CONSULTING) $114,000 Outside firm · 5 filings
• FORBES-TATE $60,000 Outside firm · 4 filings

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

• H.R. 1262
  Mikaela Naylon Give Kids a Chance Act
  5 filings
• S. 932
  Give Kids a Chance Act of 2025
  5 filings
• H.R. 1509
  Accelerating Kids’ Access to Care Act of 2025
  3 filings
• S. 752
  Accelerating Kids’ Access to Care Act
  3 filings
• H.R. 1
  One Big Beautiful Bill Act
  2 filings
• H.R. 8646
  Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
  2 filings

• 2026 $1,740,000 19 filings
• 2025 $1,094,000 12 filings

• Health Issues 26
• Budget/Appropriations 9
• Medical/Disease Research/Clinical Labs 8
• Medicare/Medicaid 6
• Government Issues 4

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

• HOUSE OF REPRESENTATIVES 22
• SENATE 22
• Health & Human Services, Dept of (HHS) 8
• Office of Management & Budget (OMB) 4
• Food & Drug Administration (FDA) 3
• Centers For Medicare and Medicaid Services (CMS) 2
• Executive Office of the President (EOP) 2